公开(公告)号：US20210369716A1

公开(公告)日：2021-12-02

申请号：US17398852

申请日：2021-08-10

Applicant: NOVARTIS AG

Inventor： Agnes BIGGART ,  Fang LIANG ,  Casey Jacob Nelson MATHISON ,  Valentina MOLTENI ,  Advait Suresh NAGLE ,  Frantisek SUPEK ,  Vince YEH

IPC: A61K31/519 ,  C07D487/04 ,  C07D519/00 ,  C07F5/02 ,  C07F7/08 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

公开(公告)号：US20190000852A1

公开(公告)日：2019-01-03

申请号：US16116418

申请日：2018-08-29

Applicant: NOVARTIS AG

Inventor： Agnes BIGGART ,  Fang LIANG ,  Casey Jacob Nelson MATHISON ,  Valentina MOLTENI ,  Advait Suresh NAGLE ,  Frantisek SUPEK ,  Vince YEH

IPC: A61K31/519 ,  A61K45/06 ,  A61K31/695 ,  A61K31/5377

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

公开(公告)号：US20170333437A1

公开(公告)日：2017-11-23

申请号：US15600183

申请日：2017-05-19

Applicant: NOVARTIS AG

Inventor： Agnes BIGGART ,  Fang LIANG ,  Casey Jacob Nelson MATHISON ,  Valentina MOLTENI ,  Advait Suresh Nagle ,  Frantisek SUPEK ,  Vince YEH

IPC: A61K31/519 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06

CPC classification number: A61K31/519 ,  A61K31/5377 ,  A61K31/695 ,  A61K45/06 ,  C07D487/04 ,  C07D519/00 ,  C07F5/027 ,  C07F7/0814

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

公开(公告)号：US20200179391A1

公开(公告)日：2020-06-11

申请号：US16780628

申请日：2020-02-03

Applicant: NOVARTIS AG

Inventor： Agnes BIGGART ,  Fang LIANG ,  Casey Jacob Nelson MATHISON ,  Valentina MOLTENI ,  Advait Suresh NAGLE ,  Frantisek SUPEK ,  Vince YEH

IPC: A61K31/519 ,  A61K45/06 ,  A61K31/695 ,  A61K31/5377 ,  C07F7/08 ,  C07F5/02 ,  C07D519/00 ,  C07D487/04

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.